Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?

Eli Lilly's GLP-1 franchises Mounjaro and Zepbound are producing nearly $12 billion in quarterly sales and management guides full-year revenue of $80–$83 billion (implying up to ~27% growth). By contrast, Novo Nordisk projects adjusted sales to decline 5%–13% amid competition from compounded copycat drugs and is litigating Hims & Hers over alleged patent infringement; successful enforcement could materially improve its outlook. Valuation spreads are wide—Lilly trades near 46x trailing earnings versus Novo at ~13x—leading the author to argue Novo may offer better upside given current pricing despite near-term headwinds.

Analysis

Market structure: Eli Lilly (LLY) is the short‑term winner — Mounjaro/Zepbound have driven ~27% top‑line growth and taken pricing power in the GLP‑1 category — while Novo Nordisk (NVO) is the immediate loser due to copycat compounded drugs eroding volumes. Compounding pharmacies and entrants like HIMS compress pricing and raise channel share for low‑price substitutes; if courts fail to restrain compounding, expected ASPs could decline by mid‑teens across the class within 6–12 months. Options and equity volatility for LLY are elevated (implied vol +20–30% vs pre‑GLP‑1), increasing premium income strategies’ attractiveness; modest risk‑on from strong pharma earnings could pressure long‑dated Treasuries by 5–15 bps if sustained.

Risk assessment: Tail risks include an adverse patent ruling or payor reimbursement cap (low probability, high impact) that could knock 20–40% off expected GLP‑1 revenue for either firm within 6–18 months. Near term (weeks) watch court filings and quarterly guidance; medium term (3–12 months) monitor prescription trends and ASPs; long term (2–5 years) the market is driven by durable obesity market penetration and new oral GLP‑1 entrants. Hidden dependencies: raw‑material bottlenecks, third‑party compounding regulation, and single‑product revenue concentration.

Trade implications: The preferred trade is a market‑neutral pair: long NVO and short LLY sized to dollar‑neutrality to capture a potential re‑rating (NVO P/E 13 → 20 = ~+50% vs LLY P/E 46 → 30 = ~‑35%). Use 12‑18 month horizon with stop losses (NVO −15%, LLY +20%); tactically buy NVO 9–12 month LEAP calls 20–30% OTM and fund with a 3–6 month LLY put spread to hedge headline risk. Reallocate 2–4% of portfolio from high‑multiple growth biotech into diversified pharma and GLP‑1 input suppliers if court rulings favor incumbents.

Contrarian angles: Consensus is overpaying for momentum at LLY and overselling NVO’s structural position — if Novo secures injunctions or wins suits within 3–6 months, sales could reaccelerate and trigger a >40% re‑rating. Historical parallels: Humira biosimilar litigation produced multi‑quarter valuation swings despite stable underlying demand; similarly, aggressive IP enforcement by NVO could be a binary catalyst. Unintended consequences: heavy shorting of LLY risks squeeze if new indications or faster international launches appear, so size accordingly and layer exposure.

Key Decisions for Investors

• Establish a dollar‑neutral pair trade: go long NVO at 2–3% of portfolio notional and short LLY at equal dollar size; target 12–18 month horizon, take profits if NVO appreciates +40% or LLY declines −25%; hard stop if NVO falls −15% or LLY rises +20%.
• Buy NVO 9–12 month LEAP calls ~20–30% OTM for a 1–2% portfolio allocation as asymmetric upside (re‑rating + litigation win) while funding with a 3–6 month LLY 10–15% OTM put spread sized to net zero cash outlay where possible.
• Trim outright LLY long exposure by 30–50% if position >3% of portfolio; redeploy proceeds into NVO and 1–2% into GLP‑1 input/supply chain names and diversified large‑cap pharma, targeting lower multiple cashflows.
• Monitor triggers over next 90 days: (1) outcome/temporary injunction on NVO vs HIMS litigation, (2) next quarter ASP/prescription trends for Mounjaro/Zepbound, and (3) any payor formulary actions; if any are positive for NVO, increase NVO allocation to 4–6% within 30 days.